GlassScriptPhysician profile
James Philip Hoffmann
NPI 1609971258
$438.58
in general payments reported to CMS, 2019-2025
13 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.20 · 2020: $12.64 · 2021: $17.14 · 2022: $15.39 · 2023: $36.17 · 2024: $73.04 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $70.05 | 2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $56.83 | 2019-2025 | Otezla, Repatha |
| Aimmune Therapeutics, INC. | $54.21 | 2025 | Zenpep |
| Novo Nordisk INC | $48.66 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $42.67 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Phathom Pharmaceuticals, INC. | $35.64 | 2024-2025 | Voquezna |
| Viiv Healthcare Company | $27.12 | 2024 | Dovato |
| Abbvie INC. | $26.84 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $17.17 | 2024 | |
| Allergan, INC. | $17.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.78 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.39 | 2019 | |
| Amarin Pharma, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.